At the time of writing, Puma Biotechnology Inc [PBYI] stock is trading at $6.6, up 3.61%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PBYI shares have gain 5.10% over the last week, with a monthly amount glided 18.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Puma Biotechnology Inc [NASDAQ: PBYI] stock has seen the most recent analyst activity on September 28, 2021, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $11 for it. On October 08, 2019, downgrade downgraded it’s rating to Sell and revised its price target to $8 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $24 on May 10, 2019. Cantor Fitzgerald downgraded its rating to a Neutral and reduced its price target to $20 on May 10, 2019. Leerink Partners started tracking with a Mkt Perform rating for this stock on January 17, 2019, and assigned it a price target of $21. In a note dated January 03, 2019, Guggenheim downgraded an Neutral rating on this stock.
For the past year, the stock price of Puma Biotechnology Inc fluctuated between $2.58 and $6.48. Puma Biotechnology Inc [NASDAQ: PBYI] shares were valued at $6.6 at the most recent close of the market.
Analyzing the PBYI fundamentals
According to Puma Biotechnology Inc [NASDAQ:PBYI], the company’s sales were 212.00M for trailing twelve months, which represents an -32.36% plunge. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.36 and Total Capital is 0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Puma Biotechnology Inc [NASDAQ:PBYI] has a current ratio of 1.74. Further, the Quick Ratio stands at 1.62, while the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 1.57, the price to book ratio is 2.88 and price to earnings (TTM) ratio is 8.91.
Transactions by insiders
Recent insider trading involved AUERBACH ALAN H, President and CEO, that happened on Jan 07 ’26 when 18012.0 shares were sold. President and CEO, AUERBACH ALAN H completed a deal on Jan 06 ’26 to sell 16938.0 shares. Meanwhile, See Remarks HUNT DOUGLAS M sold 5014.0 shares on Jan 07 ’26.
